Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics reported positive top-line data from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). In obstructive HCM, 90% of patients showed hemodynamic improvement and 74% achieved normalization or significant reduction in NT-proBNP, while nonobstructive HCM patients saw a 65% mean reduction in NT-proBNP.
Key figures
- Drug Name
- EDG-7500
- Phase Of Trial
- Phase 2
- Nchm patients
- 33
- Ochm patients
- 20
- Nchm nyha improvement
- 64%
- Ochm nyha improvement
- 70%
- Nchm kccq oss increase
- 13-point mean increase
- Ochm kccq oss increase
- 24-point mean increase
- Nchm e lateral increase
- 37%
- Ochm e lateral increase
- ~20% mean increase
- Phase3 initiation target
- fourth quarter of 2026
- Patients completed part d
- 53
- Atrial fibrillation events
- 2
- Ochm hemodynamic improvement
- 90%
- Nchm nt probnp mean reduction
- 65%
- Nchm e over e prime improvement
- 6.1 points
- Ochm e over e prime improvement
- 5.3 points
- Nchm nt probnp normalization or reduction
- 88%
- Ochm nt probnp normalization or reduction
- 74%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.